• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Ascendant Resources Announces Results of Annual and Special Meeting of Shareholders

    8/23/23 4:48:00 PM ET
    $ASND
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ASND alert in real time by email

    TSX: ASND

    www.ascendantresources.com

    • All matters overwhelmingly approved by shareholders

    TORONTO, Aug. 23, 2023 /PRNewswire/ - Ascendant Resources Inc. (TSX:ASND) (OTCQB:ASND) ("Ascendant" or the "Company") is pleased to announce the voting results of the Company's 2023 Annual and Special Shareholders' Meeting (the "Meeting") held on August 23, 2023, in Toronto, Ontario.

    Ascendant Resources Inc. Logo (CNW Group/Ascendant Resources Inc.)

    A total of 43,635,681 common shares were voted at the Meeting, representing 32.98% of the votes attached to all outstanding common shares of the Company.  All matters presented for shareholder approval at the Meeting were duly authorized and approved as follows:

    Number of Directors to be Elected

    On a vote by a show of hands, the resolution to set the number of directors to be elected at the meeting at seven (7) was approved. The following favourable votes were cast by proxy: 



    Total Votes

    % of Votes Cast

    Votes in Favour

    43,175,341

    98.95 %

    Votes Against

    460,340

    1.05 %

    Total Votes Cast

    43,635,681

    100 %

    Election of Directors

    The shareholders elected each of the seven nominees listed in the Company's Management Proxy Circular.  Details of the voting results are as follows

    Name

    Votes in Favour

    %

    Votes Withheld

    %

    Mark Brennan

    42,263,782

    98.83 %

    501,592

    1.17

    Robert Campbell

    42,494,276

    99.37 %

    271,098

    0.63

    Christopher Jones

    38,656,682

    90.39 %

    4,108,692

    9.61

    Kurt Menchen

    38,653,276

    90.38 %

    4,112,098

    9.62

    Rui Botica Santos

    38,653,276

    90.38 %

    4,112,098

    9.62

    Robert Sellars

    38,653,276

    90.38 %

    4,112,098

    9.62

    Stephen Shefsky

    38,653,276

    90.38 %

    4,112,098

    9.62

    Appointment of Auditors

    KPMG LLP was appointed auditor of the Corporation and the directors of the Corporation were authorized to fix the auditor's remuneration.  Details of the voting results are as follows:



    Total Votes

    % of Votes Cast

    Votes in Favour

    43,178,747

    98.95 %

    Votes Withheld

    456,934

    1.05 %

    Total Votes Cast

    43,635,681

    100 %

    Amended and Restated Omnibus Incentive Plan

    A ballot was conducted with respect to the Amended and Restated Omnibus Incentive Plan of the Corporation.  According to the proxies received and ballots cast by shareholders, the resolution to approve the Amended and Restated Omnibus Incentive Plan of the Corporation was approved.



    Total Votes

    % of Votes Cast

    Votes in Favour

    38,283,059

    89.52 %

    Votes Against

    4,482,315

    10.48 %

    Total Votes Cast

    42,765,374

    100 %

    About Ascendant Resources Inc.

    Ascendant Resources is a Toronto-based mining company focused on the exploration and development of the highly prospective Lagoa Salgada VMS project located on the prolific Iberian Pyrite Belt in Portugal. The Lagoa Salgada project is a high-grade polymetallic project, demonstrating a typical mineralization endowment of zinc, copper, lead, tin, silver, and gold. Extensive exploration upside potential lies both near deposit and at prospective step-out targets across the large 7,209-hectare property concession.

    Located just 80km from Lisbon and surrounded by exceptional infrastructure, Lagoa Salgada offers a low-cost entry to a significant exploration and development opportunity, already showing its mineable scale and cashflow generation potential.

    Ascendant currently holds 80% interest in the Lagoa Salgada project through its position in Redcorp - Empreendimentos Mineiros, Lda, ("Redcorp").  The Company's common shares are principally listed on the Toronto Stock Exchange under the symbol "ASND". For more information on Ascendant, please visit our website at http://www.ascendantresources.com/.

    Additional information relating to the Company, including the Preliminary Economic Assessment referenced in this news release, is available on SEDAR at www.sedar.com.

    Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/ascendant-resources-announces-results-of-annual-and-special-meeting-of-shareholders-301908518.html

    SOURCE Ascendant Resources Inc.

    Get the next $ASND alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ASND

    DatePrice TargetRatingAnalyst
    11/18/2025$255.00Peer Perform
    Wolfe Research
    10/17/2025$271.00Strong Buy
    Raymond James
    7/3/2025$250.00Overweight
    Morgan Stanley
    5/5/2025$250.00Equal-Weight → Overweight
    Morgan Stanley
    4/16/2025$205.00Outperform
    RBC Capital Mkts
    1/7/2025$196.00Buy
    UBS
    9/5/2024$180.00Perform → Outperform
    Oppenheimer
    6/25/2024$156.00 → $175.00Hold → Buy
    TD Cowen
    More analyst ratings

    $ASND
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13G/A filed by Ascendis Pharma A/S

    SCHEDULE 13G/A - Ascendis Pharma A/S (0001612042) (Subject)

    11/14/25 11:54:23 AM ET
    $ASND
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 6-K filed by Ascendis Pharma A/S

    6-K - Ascendis Pharma A/S (0001612042) (Filer)

    11/12/25 4:39:25 PM ET
    $ASND
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 6-K filed by Ascendis Pharma A/S

    6-K - Ascendis Pharma A/S (0001612042) (Filer)

    11/12/25 4:15:33 PM ET
    $ASND
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ASND
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Wolfe Research initiated coverage on Ascendis Pharma with a new price target

    Wolfe Research initiated coverage of Ascendis Pharma with a rating of Peer Perform and set a new price target of $255.00

    11/18/25 8:20:21 AM ET
    $ASND
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Raymond James initiated coverage on Ascendis Pharma with a new price target

    Raymond James initiated coverage of Ascendis Pharma with a rating of Strong Buy and set a new price target of $271.00

    10/17/25 8:28:03 AM ET
    $ASND
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Morgan Stanley resumed coverage on Ascendis Pharma with a new price target

    Morgan Stanley resumed coverage of Ascendis Pharma with a rating of Overweight and set a new price target of $250.00

    7/3/25 7:49:10 AM ET
    $ASND
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ASND
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Results of Pivotal ApproaCH Trial of TransCon® CNP (Navepegritide) in Children with Achondroplasia Published in JAMA Pediatrics

    COPENHAGEN, Denmark, Nov. 17, 2025 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (NASDAQ:ASND) today announced that pivotal Week 52 results from its randomized double-blind, placebo-controlled ApproaCH Trial of investigational once-weekly TransCon® CNP (navepegritide) in children with achondroplasia have been published in JAMA Pediatrics, a journal of the American Medical Association. In the publication, titled "Once-Weekly Navepegritide in Children with Achondroplasia: The ApproaCH Randomized Clinical Trial," the authors report that treatment with TransCon CNP led to significantly higher annualized growth velocity (AGV) at Week 52 compared to placebo (primary endpoint), as well as improved lowe

    11/17/25 4:01:00 PM ET
    $ASND
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Ascendis Pharma Reports Third Quarter 2025 Financial Results

    –   Q3 2025 revenue of €143.1 million for YORVIPATH® and €50.7 million for SKYTROFA® –   Q3 2025 operating profit of €11.0 million –   TransCon® CNP (navepegritide) under FDA Priority Review for the treatment of children with achondroplasia with PDUFA date of November 30, 2025 –   Conference call today at 4:30 pm ET COPENHAGEN, Denmark, Nov. 12, 2025 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (NASDAQ:ASND) today announced financial results for the third quarter ended September 30, 2025, and provided a business update. "With our achievements in the third quarter and year to date, Ascendis is making great progress toward achieving Vision 2030. The ongoing strong global launch of YORVIPATH

    11/12/25 4:01:00 PM ET
    $ASND
    Biotechnology: Pharmaceutical Preparations
    Health Care

    New Pooled 3-Year Analysis Confirms Sustained, Clinically Meaningful Improvements in Renal Function for TransCon® PTH (Palopegteriparatide)-Treated Adults with Hypoparathyroidism

    COPENHAGEN, Denmark, Nov. 07, 2025 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (NASDAQ:ASND) today announced that a new pooled analysis showed sustained and clinically meaningful improvements in renal function in adults with hypoparathyroidism treated with TransCon PTH (palopegteriparatide) through Year 3 of the Company's Phase 2 PaTH Forward and Phase 3 PaTHway trials. The data, which confirm results for each individual trial presented at major endocrinology meetings earlier this year, were shared during Kidney Week 2025 in a poster presented by lead author Dr. Elvira Gosmanova, a nephrologist at Albany Medical College and Albany VAMC (New York). "The magnitude and trajectory of improvement

    11/7/25 8:30:00 AM ET
    $ASND
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ASND
    Leadership Updates

    Live Leadership Updates

    View All

    Ascendant Resources Announces Results of Annual General Meeting of Shareholders

    TORONTO, ON / ACCESSWIRE / June 13, 2024 / Ascendant Resources Inc. (TSX:ASND)(OTCQB:ASND) ("Ascendant" or the "Company") is pleased to announce the voting resultsof the Company's 2024 Annual General Shareholders' Meeting (the "Meeting") held on June 13, 2024, in Toronto, Ontario.A total of 51,497,589 common shares were voted at the Meeting, representing 27.59% of the votes attached to all outstanding common shares of the Company. All matterspresented for shareholder approval at the Meeting were duly authorized and approved as follows:Number of Directors to be ElectedOn a vote by a show of hands, the resolution to set the number of directors to be elected at the meeting at six (6) was approv

    6/13/24 5:55:00 PM ET
    $ASND
    Biotechnology: Pharmaceutical Preparations
    Health Care

    New Company Eyconis Formed to Develop Ascendis Pharma Ophthalmology Assets with $150 Million Commitment from External Investors

    COPENHAGEN, Denmark, Jan. 29, 2024 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (NASDAQ:ASND) today announced the formation and launch with Frazier Life Sciences of Eyconis, Inc., a separate company created to develop, manufacture, and commercialize TransCon ophthalmology assets globally, together with an investor syndicate that includes Frazier, RA Capital Management, venBio, and HealthQuest Capital. Ascendis Pharma has granted Eyconis exclusive rights to develop and commercialize TransCon ophthalmology products globally and received an equity position in the newly formed company. In addition, Ascendis will be eligible to receive development, regulatory, and sales milestone payments of up to

    1/29/24 8:30:00 AM ET
    $ASND
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Ascendant Resources Announces Results of Annual and Special Meeting of Shareholders

    TSX: ASNDwww.ascendantresources.com All matters overwhelmingly approved by shareholdersTORONTO, Aug. 23, 2023 /PRNewswire/ - Ascendant Resources Inc. (TSX:ASND) (OTCQB:ASND) ("Ascendant" or the "Company") is pleased to announce the voting results of the Company's 2023 Annual and Special Shareholders' Meeting (the "Meeting") held on August 23, 2023, in Toronto, Ontario. A total of 43,635,681 common shares were voted at the Meeting, representing 32.98% of the votes attached to all outstanding common shares of the Company.  All matters presented for shareholder approval at the Me

    8/23/23 4:48:00 PM ET
    $ASND
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ASND
    Financials

    Live finance-specific insights

    View All

    Ascendis Pharma Reports Third Quarter 2025 Financial Results

    –   Q3 2025 revenue of €143.1 million for YORVIPATH® and €50.7 million for SKYTROFA® –   Q3 2025 operating profit of €11.0 million –   TransCon® CNP (navepegritide) under FDA Priority Review for the treatment of children with achondroplasia with PDUFA date of November 30, 2025 –   Conference call today at 4:30 pm ET COPENHAGEN, Denmark, Nov. 12, 2025 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (NASDAQ:ASND) today announced financial results for the third quarter ended September 30, 2025, and provided a business update. "With our achievements in the third quarter and year to date, Ascendis is making great progress toward achieving Vision 2030. The ongoing strong global launch of YORVIPATH

    11/12/25 4:01:00 PM ET
    $ASND
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Ascendis Pharma to Report Third Quarter 2025 Financial Results and Provide Business Update on November 12, 2025

    COPENHAGEN, Denmark, Nov. 05, 2025 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (NASDAQ:ASND) today announced it plans to report third quarter 2025 financial results and provide a business update on Wednesday, November 12, 2025, after the close of the U.S. financial markets. Ascendis Pharma also plans to host a conference call and live webcast on November 12, 2025, at 4:30 p.m. Eastern Time (ET) to discuss its third quarter 2025 financial results. Those who would like to participate may access the live webcast here, or register in advance for the teleconference here. The link to the live webcast will also be available on the Investors & News section of the Ascendis Pharma website at https://in

    11/5/25 4:01:00 PM ET
    $ASND
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Ascendis Pharma Reports Second Quarter 2025 Financial Results

    – Q2 2025 revenue of €103.0 million for YORVIPATH® and €50.7 million for SKYTROFA® – TransCon® CNP (navepegritide) NDA under Priority Review for the treatment of children with achondroplasia with PDUFA date of November 30, 2025 – SKYTROFA® (lonapegsomatropin-tcgd) approved in the U.S. for treatment of adults with growth hormone deficiency; first of many planned label expansions  – Week 26 Interim Results for COACH trial highlight the unique portfolio of once-weekly TransCon CNP and once-weekly TransCon hGH, with complementary modes of action, to potentially further transform the treatment landscape for growth disorders and physical functioning –Conference call today at 4:30 pm ET COPENH

    8/7/25 4:01:00 PM ET
    $ASND
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ASND
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Ascendis Pharma A/S

    SC 13G/A - Ascendis Pharma A/S (0001612042) (Subject)

    11/14/24 5:46:12 PM ET
    $ASND
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Ascendis Pharma A/S

    SC 13G/A - Ascendis Pharma A/S (0001612042) (Subject)

    11/14/24 2:57:14 PM ET
    $ASND
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Ascendis Pharma A/S

    SC 13G/A - Ascendis Pharma A/S (0001612042) (Subject)

    11/14/24 1:28:32 PM ET
    $ASND
    Biotechnology: Pharmaceutical Preparations
    Health Care